Publication:
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

Simple item page
dc.contributor.authorIborra-Egea, Oriol
dc.contributor.authorSantiago-Vacas, Evelyn
dc.contributor.authorYurista, Salva R
dc.contributor.authorLupón, Josep
dc.contributor.authorPacker, Milton
dc.contributor.authorHeymans, Stephane
dc.contributor.authorZannad, Faiez
dc.contributor.authorButler, Javed
dc.contributor.authorPascual-Figal, Domingo A
dc.contributor.authorLax, Antonio
dc.contributor.authorNúñez, Julio
dc.contributor.authorde Boer, Rudolf A
dc.contributor.authorBayes-Genis, Antoni
dc.date.accessioned2020-04-21T12:14:41Z
dc.date.available2020-04-21T12:14:41Z
dc.date.issued2019-11
dc.description.abstractThe mechanism of action of empagliflozin in heart failure with reduced ejection fraction (HFrEF) was deciphered using deep learning in silico analyses together with in vivo validation. The most robust mechanism of action involved the sodium-hydrogen exchanger (NHE)-1 co-transporter with 94.7% accuracy, which was similar for diabetics and nondiabetics. Notably, direct NHE1 blockade by empagliflozin ameliorated cardiomyocyte cell death by restoring expression of X-linked inhibitor of apoptosis (XIAP) and baculoviral IAP repeat-containing protein 5 (BIRC5). These results were independent of diabetes mellitus comorbidity, suggesting that empagliflozin may emerge as a new treatment in HFrEF.es_ES
dc.description.peerreviewedSíes_ES
dc.format.number7es_ES
dc.format.page831-840es_ES
dc.format.volume4es_ES
dc.identifier.citationJACC Basic Transl Sci. 2019; 4(7):831-840es_ES
dc.identifier.doi10.1016/j.jacbts.2019.07.010es_ES
dc.identifier.e-issn2452-302Xes_ES
dc.identifier.issn2452-302Xes_ES
dc.identifier.journalJACC. Basic to translational sciencees_ES
dc.identifier.pubmedID31998851es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9658
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jacbts.2019.07.010es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectANN, artificial neural networkes_ES
dc.subjectDM, diabetes mellituses_ES
dc.subjectHF, heart failurees_ES
dc.subjectHFrEF, HF with reduced ejection fractiones_ES
dc.subjectMI-HF, post-infarct heart failurees_ES
dc.subjectNHE, sodium-hydrogen exchangeres_ES
dc.subjectRNAseq, RNA sequencinges_ES
dc.subjectSGLT2i, sodium-glucose co-transporter 2 inhibitores_ES
dc.subjectEmpagliflozines_ES
dc.subjectHeart failurees_ES
dc.subjectMachine learninges_ES
dc.titleUnraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabeteses_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione15445a1-38b4-496b-86ca-6992a03bed1a
relation.isAuthorOfPublication.latestForDiscoverye15445a1-38b4-496b-86ca-6992a03bed1a

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
UnravelingMolecularMechanismAction_2020.pdf
Size:
1.06 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Grupos de investigación